IGF2 Polyclonal Antibody, Cy3 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-0015R-Cy3 |
| Product Name | IGF2 Polyclonal Antibody, Cy3 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Rat |
| Predicted Reactivity | Mouse, Dog, Cow, Sheep, Pig, Rabbit |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human IGF II |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 3481 |
| Swiss Prot | P01344 |
| Subcellular location | Secreted |
| Synonyms | IGF-II; PP9974; C11orf43; Insulin-like growth factor II; Somatomedin-A; IGF2; PP1446 |
| Background | The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development. Preptin undergoes glucose-mediated co-secretion with insulin, and acts as physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |